2016 Press/Media Releases:

OPKO Announces Appointment of Thomas Nusbickel as Senior Vice President of Pharmaceutical Marketing and Market Access

MIAMI–(BUSINESS WIRE) May 10, 2016 – OPKO Health, Inc. (NYSE:OPK) today announced the appointment of Thomas Nusbickel as Senior Vice President of Pharmaceutical Marketing and Market Access to support the anticipated launch of RAYALDEE®.

Mr. Nusbickel has over 25 years of pharmaceutical experience with established large companies, such as Hospira, Amgen and Abbott, with a career long focus on specialty products and nephrology. He has been involved in numerous product launches including serving as the global lead for Amgen's launch of Sensipar, and has deep connections with managed care organizations and with key nephrology opinion leaders. Prior to joining OPKO, Mr. Nusbickel served as Hospira's Head of U.S. Market Access, Biologics and as Amgen's Executive Director, Value Access and Advocacy.

"OPKO is proud to add Tom to our growing management team responsible for commercializing RAYALDEE in the U.S. Tom has extensive, successful experience in launching new products in the U.S. chronic kidney disease market," said Phillip Frost, M.D., Chairman and Chief Executive Officer of OPKO, "and we are confident that he will help drive Rayaldee to great success."

About OPKO Health, Inc.
OPKO Health, Inc. is a diversified healthcare company that seeks to establish industry-leading positions in large, rapidly growing markets. Our diagnostics business includes Bio-Reference Laboratories, the nation's third-largest clinical laboratory with a core genetic testing business and a 420-person sales force to drive growth and leverage new products, including the 4Kscore® prostate cancer test and the Claros®1 in-office immunoassay platform. Our pharmaceutical business features Rayaldee™, a treatment for secondary hyperparathyroidism in stage 3-4 chronic kidney disease patients with vitamin D insufficiency and VARUBI™ for chemotherapy-induced nausea and vomiting (oral formulation launched by partner Tesaro, IV formulation in Phase 3). Our biologics business includes hGH-CTP, a once-weekly human growth hormone injection (in Phase 3 and partnered with Pfizer), a long-acting Factor VIIa drug for hemophilia (in Phase 2a) and a long acting oxyntomodulin for diabetes and obesity (in Phase 1). We also have production and distribution assets worldwide, multiple strategic investments and an active business development strategy. More information is available at www.opko.com.

View source version on businesswire.com

OPKO Health, Inc.
Investor Relations
Tara Mackay, 305-575-4100

Media
Rooney & Associates
Terry Rooney, 212-223-0689
Marion Janic, 212-223-4017

Investors
LHA
Anne Marie Fields, 212-838-3777
Bruce Voss, 310-691-7100

Source: OPKO Health, Inc.
News Provided by Acquire Media

 
     
     
 
   

© 2018 OPKO Health Inc.- All rights reserved. | Privacy Policy | Terms Of Use